Zilucoplan as Plan B—Complement Inhibition as Rescue Therapy for Refractory Myasthenic Crisis in Thymomatous Myasthenia Gravis

IntroductionStandard therapies for myasthenic crisis (MC) include intravenous immunoglobulin (IVIG) and plasma exchange (PLEx).A subset of patients deteriorates despite these treatments, and conventional immunosuppressants are too slow to address acute crises [1,2].There is a need for alternative rapidly acting agents.Complement activation at the post-synaptic membrane plays a key role in myasthenia gravis (MG) pathogenesis.Zilucoplan is a novel subcutaneous small-molecule inhibitor of complement protein C5, blocking formation of the membrane attack complex [3].Randomized controlled trial (RCT) data confirm its efficacy and tolerability in acetylcholine-receptor (AChR)-positive generalized MG, with clinical improvements observed within the first week of treatment [4].As MC patients were excluded from these trials, the role of zilucoplan in crisis management remains unclear.

Authors

Institutions

Publication Details

Journal
Muscle & Nerve
Published
2026-11-17
DOI
https://doi.org/10.1002/mus.70463
Primary Topic
Myasthenia Gravis and Thymoma
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Zilucoplan as Plan B—Complement Inhibition as Rescue Therapy for Refractory Myasthenic Crisis in Thymomatous Myasthenia Gravis

Stephen R. Duma, Daniel Guilfoyle, J. Wang, P. Lira
Muscle & Nerve
Myasthenia Gravis and Thymoma
article

Zilucoplan as Plan B—Complement Inhibition as Rescue Therapy for Refractory Myasthenic Crisis in Thymomatous Myasthenia Gravis

Stephen R. Duma, Daniel Guilfoyle, J. Wang, P. Lira
article en

Abstract

IntroductionStandard therapies for myasthenic crisis (MC) include intravenous immunoglobulin (IVIG) and plasma exchange (PLEx).A subset of patients deteriorates despite these treatments, and conventional immunosuppressants are too slow to address acute crises [1,2].There is a need for alternative rapidly acting agents.Complement activation at the post-synaptic membrane plays a key role in myasthenia gravis (MG) pathogenesis.Zilucoplan is a novel subcutaneous small-molecule inhibitor of complement protein C5, blocking formation of the membrane attack complex [3].Randomized controlled trial (RCT) data confirm its efficacy and tolerability in acetylcholine-receptor (AChR)-positive generalized MG, with clinical improvements observed within the first week of treatment [4].As MC patients were excluded from these trials, the role of zilucoplan in crisis management remains unclear.

Muscle & Nerve
Sutherland Hospital (AU), St George Hospital (AU)
Good health and well-being
Myasthenia Gravis and Thymoma
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon